

CITATION REPORT

List of articles citing

Impact of obesity on plasma natriuretic peptide levels

DOI: 10.1161/01.cir.0000112582.16683.ea
Circulation, 2004, 109, 594-600.

Source: <https://exaly.com/paper-pdf/36499380/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
807	Plasma brain natriuretic peptide and N-terminal proatrial natriuretic peptide levels in obese patients: a cause or result of hypertension?. <i>Circulation</i> , 2004 , 110, e76; author reply e76	16.7	13
806	Natriuretic peptides as markers of preclinical cardiac disease in obesity. 2004 , 34, 342-8		33
805	BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. 2004 , 10, 1-30		230
804	The natriuretic peptides in cardiovascular medicine. 2004 , 29, 707-69		119
803	Impact of obesity on the risk of heart failure and survival after the onset of heart failure. 2004 , 88, 1273-94		82
802	BNP--Considering a heartfelt message. 2004 , 13 Suppl 3, S31-7		1
801	Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. 2004 , 349, 25-38		36
800	Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. 2004 , 54, 1369-73; discussion 1373-4		130
799	Neuroendocrine changes in sleep apnea. 2004 , 10, 475-81		22
798	B-type natriuretic peptide: issues for the intensivist and pulmonologist. 2005 , 33, 2094-13		79
797	B-type natriuretic peptide in heart failure: diagnostic, prognostic, and therapeutic use. 2005 , 4, 10-20		14
796	Current World Literature. 2005 , 14, 283-313		
795	Kidneys extract BNP and NT-proBNP in healthy young men. 2005 , 99, 1676-80		57
794	Plasma BNP in patients on maintenance haemodialysis: a guide to management?. 2005 , 23, 23-8		15
793	Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). 2005 , 109, 69-74		33
792	Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. 2005 , 45, 573-80		73
791	The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea. 2005 , 258, 77-85		32

790	Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. 2005 , 80, 174-80		45
789	[Natriuretic peptides: a new lipolytic pathway in human fat cells]. 2005 , 21, 61-5		13
788	Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction. 2005 , 1, 7-13		
787	Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension. 2005 , 26, 385-93		9
786	Brain natriuretic peptide release in cardiac surgery patients. 2005 , 53, 138-43		19
785	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: Summary Article. <i>Circulation</i> , 2005 , 112, 1825-1852	16.7	334
784	An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. 2005 , 25, 2032-42		91
783	N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. 2005 , 51, 138-43		29
782	N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. 2005 , 46, 660-6		140
781	Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. <i>Circulation</i> , 2005 , 112, 2163-8	16.7	333
780	Natriuretic peptides and remodeling in heart failure. 2005 , 1, 129-39		4
779	B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. 2005 , 80, 1029-36		69
778	Monitoring of patients with heart failure. 2005 , 240, 99-106		7
777	Mechanisms, pathophysiology, and therapy of arterial stiffness. 2005 , 25, 932-43		1183
776	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians. <i>Circulation</i> , 2005 , 112, e154-235	16.7	1915
775	Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. 2005 , 149, 187-9		11
774	Screening for heart disease in diabetic subjects. 2005 , 149, 349-54		103
773	Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 2005 , 149, 744-50		211

772	NT-ProBNP: the mechanism behind the marker. 2005 , 11, S81-3	128
771	B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. 2005 , 11, 705-12	22
770	Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. 2005 , 46, 838-44	126
769	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). 2005 , 46, e1-82	1119
768	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Summary Article. 2005 , 46, 1116-1143	314
767	The heart in obesity-hypertension. 2005 , 3, 647-58	20
766	Cardiovascular Biomarkers. 2006 ,	2
765	BNP for clinical monitoring of heart failure. 2006 , 2, 333-43	9
764	The role of natriuretic peptides in cardioprotection. 2006 , 69, 318-28	338
763	Analytic Issues for Clinical Use of B-Type Natriuretic Peptide and N-Terminal Pro B-Type Natriuretic Peptide. 2006 , 373-385	
762	Natriuretic Peptides. 2006 ,	9
761	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. 2006 , 22, 393-7	22
760	Clinical Applications in Extra-Cardiac Diseases. 2006 , 133-160	1
759	Natriuretic peptides as diagnostic test: lessons from the first 5 years of clinical application. 2006 , 2, 299-309	4
758	Renal disease in obesity: the need for greater attention. 2006 , 16, 216-23	71
757	Natriuretic peptides in screening for cardiac dysfunction. 2006 , 2, 323-32	1
756	C-reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives. 2006 , 29, 411-5	10
755	B-type natriuretic peptide levels in obese patients with advanced heart failure. 2006 , 47, 85-90	186

754	Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. 2006 , 47, 345-53	305
753	Is brain natriuretic peptide production decreased in obese subjects?. 2006 , 47, 886-7	42
752	Death or heart failure post acute myocardial infarction? The role of cardiac biomarkers. 2006 , 12, 641-3	3
751	Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. 2006 , 91, 5069-75	45
750	B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. 2006 , 52, 680-5	56
749	B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. 2006 , 152, 1071-6	120
748	Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. 2006 , 151, 471-7	52
747	How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. 2006 , 151, 999-1005	205
746	Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. 2006 , 151, 1006-11	50
745	Low prevalence of B-type natriuretic peptide levels 2006, 151, 1012.e1-5	14
744	The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. 2006 , 1, 117727190600100	0
743	Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. 2006 , 29, 1301-6	38
742	B-type natriuretic peptide concentrations and myocardial dysfunction in critical illness. 2006 , 34, 151-63	4
741	Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. 2006 , 70, 482-8	23
740	Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. 2006 , 166, 1081-7	90
739	Clinical application of the natriuretic peptides in heart failure. 2006 , 8, E18-E25	20
738	[Physiological and pathophysiological features of the control of lipolysis and lipid mobilization by natriuretic peptides]. 2006 , 200, 67-76	1
737	Cardiovascular and metabolic effects of natriuretic peptides. 2006 , 20, 41-9	18

736	Maximum longitudinal relaxation velocity of the left ventricle: its clinical value and relationship with NT-proBNP plasma levels in heart failure. 2006 , 23, 295-302	4
735	BNP and N-terminal proBNP are both extracted in the normal kidney. 2006 , 36, 8-15	71
734	Substantial intraindividual variability of BNP concentrations in patients with hypertension. 2006 , 20, 387-91	18
733	Assessment of BNP and NT-proBNP in emergency department patients presenting with suspected acute coronary syndromes. 2006 , 39, 11-8	14
732	[Are neurohumoral parameters predictive for the efficacy of cardiac resynchronization therapy? The role of natriuretic peptides]. 2006 , 17 Suppl 1, I51-5	1
731	The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea. 2006 , 49, 629-36	6
730	Screening for ventricular remodeling. 2006 , 3, 5-13	7
729	Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. 2006 , 12, 85-90	13
728	Optimizing treatment and outcomes in acute heart failure: beyond initial triage. 2006 , 12, 137-45	10
727	Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic peptide associated with obesity and hyperleptinemia. 2006 , 37, 307-15	7
726	The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. 2006 , 27, 2353-61	75
725	Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure. 2006 , 7, 45-52	10
724	Natriuretic peptides in the diagnosis and management of heart failure. 2006 , 175, 611-7	71
723	Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure. 2006 , 8, 263-9	7
722	B-type natriuretic peptides as powerful markers in cardiac diseases Analytical and clinical aspects / B-Typ natriuretische Peptide als aussagekräftige Marker bei kardialen Erkrankungen Analytische und klinische Aspekte. 2006, 30, 165-184	
721	Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. 2006 , 290, H17-29	199
720	Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients. 2006 , 8, 621-7	36
719	Non-cardiac determinants of NT-proBNP levels in the elderly: relevance of haematocrit and hepatic steatosis. 2006 , 8, 468-76	23

718	Treatment of Advanced Heart Disease. 2006,		1
717	Obesity and Diabetes. 2006,		4
716	Prognostic value of NH2-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. 2006, 29, 1411-3		7
715	B-type natriuretic peptides as powerful markers in cardiac diseases: Analytical and clinical aspects. 2006, 25, 287-308		
714	The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. 2006, 43, 184-8		5
713	Diet, Metabolic Syndrome, and Obesity. 2006, 37-58		
712	Natriuretic peptides: update on Peptide release, bioactivity, and clinical use. 2007, 50, 25-30		38
711	Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. 2007, 53, 1415-22		42
710	Metabolic regulation: effects of natriuretic peptide interactions. 2007, 2, 607-614		4
709	The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. 2007, 21, 546-50		13
708	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation,</i> 2007, 116, 627-36	16.7	264
707	Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. 2007, 9, 667-73		25
706	Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. <i>Circulation,</i> 2007, 115, 1345-53	16.7	166
705	B-type natriuretic peptides in heart failure: update on clinical applications and limitations. 2007, 1, 503-12		2
704	The future of implantable hemodynamic monitors. 2007, 3, 579-82		1
703	Brain natriuretic peptide: does it play a role in post-cardiac surgery patients?. 2007, 3, 109-13		
702	Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. 2007, 16, 1343-50		64
701	Biomarkers for prediction of cardiovascular events. 2007, 356, 1472; author reply 1474-5		30

700	Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies. 2007 , 53, 2097-104		22
699	Brain Natriuretic Peptide (BNP). 2007 , 357-360		
698	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. 2007 , 25, 833-9		34
697	Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. 2007 , 362, 480-4		32
696	BNP in overweight and obese patients with heart failure: an analysis based on the BNP-LV diastolic wall stress relationship. 2007 , 13, 663-7		25
695	Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures: review of the literature and clinical recommendations. 2007 , 23, 983-9		21
694	Sex differences in lipolysis-regulating mechanisms in overweight subjects: effect of exercise intensity. 2007 , 15, 2245-55		29
693	Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. 2007 , 7, 793-804		22
692	National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. <i>Circulation</i> , 2007 , 116, e99-109	16.7	186
691	Obesity cardiomyopathy: diagnosis and therapeutic implications. 2007 , 4, 480-90		47
690	Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. 2007 , 148, 2075-84		75
689	Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. 2007 , 30, 741-53		57
688	Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. 2007 , 49, 109-16		122
687	Natriuretic peptides. 2007 , 50, 2357-68		774
686	Natriuretic Peptides. 2007 , 349-362		1
685	N-terminal-pro-brain natriuretic peptide, but not brain natriuretic peptide, is increased in patients with severe obesity. 2007 , 40, 153-158		7
684	A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5'-flanking region is associated with essential hypertension among Japanese females. 2007 , 4, 146-52		10
683	Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes. 2007 , 15, 2181-9		15

682	Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. 2007 , 152, 1102-10	37
681	N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. 2007 , 66, 619-25	12
680	Usefulness of B-type natriuretic peptide levels to predict left ventricular filling pressures in patients with body mass index >35, 31 to 35, and 2007, 100, 1166-71	11
679	Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. 2007 , 30, 245-50	34
678	Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. 2007 , 50, 1038-47	90
677	Le peptide atrial natriurétique: un lien fonctionnel entre métabolisme et inflammation du tissu adipeux. 2007 , 2, 254-259	
676	The relationship between tissue Doppler imaging and seric NTproBNP levels in sinus rhythm patients: a prospective study. 2008 , 24, 399-407	7
675	N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea. 2008 , 12, 7-16	23
674	Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP. 2008 , 177, 197-203	2
673	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. 2008 , 41, 210-21	53
672	Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. 2008 , 32, 259-67	50
671	Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?. 2008 , 35, 442-6	8
670	Amino-terminal pro-B-type natriuretic peptides: testing in general populations. 2008 , 101, 16-20	27
669	Understanding amino-terminal pro-B-type natriuretic peptide in obesity. 2008 , 101, 89-94	41
668	Effect of nasal continuous positive airway pressure in men on global left ventricular myocardial performance in patients with obstructive sleep apnea syndrome. 2008 , 101, 1796-800	18
667	Emergency Department Perspectives on B-Type Natriuretic Peptide Utility. 2008 , 14, 17-20	8
666	Emergency department perspectives on B-type natriuretic peptide utility. 2008 , 14, 17-20	3
665	Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. 2008 , 136, 452-61	48

664	Diastolic Heart Failure. 2008 ,	3
663	Relationship between slightly elevated NT-proBNP and alterations in diastolic function detected by echocardiography in patients without structural heart disease. 2008 , 129, 430-2	2
662	Use of B-type natriuretic peptide outside of the emergency department. 2008 , 127, 5-16	32
661	BNP or NTproBNP? A clinician's perspective. 2008 , 129, 5-14	45
660	Biomarkers for cardiovascular disease: challenges and future directions. 2008 , 14, 261-7	31
659	NT-proBNP is not elevated in patients with obstructive sleep apnoea. 2008 , 102, 134-42	22
658	Control of lipolysis by natriuretic peptides and cyclic GMP. 2008 , 19, 130-7	173
657	Relationship between morning hypertension identified by home blood pressure monitoring and brain natriuretic peptide and estimated glomerular filtration rate: the Japan Morning Surge 1 (JMS-1) Study. 2008 , 10, 34-42	26
656	B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. 2008 , 34, 355-62	29
655	Natriuretic peptides and filling pressure at rest and stress. 2008 , 4, 71-86	14
654	Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus. 2008 , 6, 109-25	9
653	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 2008 , 46, 1515-23	16
652	Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure". 2008 , 94, 748-53	26
651	Relation between body mass index, waist circumference, and death after acute myocardial infarction. <i>Circulation</i> , 2008 , 118, 482-90	16.7 111
650	Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. 2008 , 29, 2227-33	195
649	Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. 2008 , 29, 2634-40	30
648	Dynamic left ventricular dyssynchrony contributes to B-type natriuretic peptide release during exercise in patients with systolic heart failure. 2008 , 10, 496-501	10
647	Review on natriuretic peptides: where we are, where we are going. 2008 , 2, 1137-53	1

646	Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. 2008 , 21, 733-41	153
645	Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study. 2008 , 5, 19-24	4
644	Management of Heart Failure. 2008 ,	1
643	Association of a polymorphism in the lipin 1 gene with systolic blood pressure in men. 2008 , 21, 539-45	26
642	Exercise-induced biphasic increase in circulating NT-proBNP levels in patients with chronic heart failure. 2008 , 10, 793-5	2
641	Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. 2008 , 3, 407-15	49
640	Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels. 2008 , 21, 820-5	9
639	Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. 2008 , 31, 825-31	24
638	Atrial natriuretic peptide induces postprandial lipid oxidation in humans. 2008 , 57, 3199-204	96
637	Impairment of the natriuretic peptide system in follitropin receptor knockout mice and reversal by estradiol: implications for obesity-associated hypertension in menopause. 2008 , 149, 1399-406	27
636	State of the art: using natriuretic peptide levels in clinical practice. 2008 , 10, 824-39	529
635	Clinical significance of B-type natriuretic Peptide in the assessment of untreated hypertension. 2008 , 72, 770-7	16
634	Brain natriuretic peptide in cardiovascular diseases. 2008 , 335, 477-83	1
633	Use of Natriuretic Peptides in the Diagnosis of Heart Failure. 93-115	
632	Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure. 140-158	
631	Plasma B-type natriuretic peptide level is associated with left ventricular hypertrophy among obstructive sleep apnoea patients. 2008 , 26, 117-23	18
630	Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. 2008 , 26, 831-43	206
629	. 2008 ,	1

628 Role of Neurohormones. **2008**, 345-366

627	N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. 2009 , 39, 538-44		11
626	The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects. 2009 , 18, 2495-501		26
625	Association of parental obesity with concentrations of select systemic biomarkers in nonobese offspring: the Framingham Heart Study. 2009 , 58, 134-7		26
624	2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. <i>Circulation</i> , 2009 , 119, 1977-2016	16.7	1178
623	Body mass and atherogenic dyslipidemia as major determinants of blood levels of B-type natriuretic peptides in Arab subjects with acute coronary syndromes. 2009 , 7, 563-9		3
622	Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. 2009 , 22, 425-31		18
621	2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. <i>Circulation</i> , 2009 , 119, 1977-2016	16.7	1254
620	Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide. 2009 , 3, 465-81		11
619	Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. 2009 , 58, 2880-92		214
618	Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. 2009 , 11, 1043-9		9
617	Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure. 2009 , 43, 324-9		4
616	Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome. 2009 , 103, 1736-40		16
615	Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. 2009 , 104, 689-94		25
614	Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). 2009 , 104, 1245-50		12
613	[NT-proBNP in practice: from chemistry to medicine]. 2009 , 58, 165-79		5
612	Marqueurs biochimiques de l'insuffisance cardiaque (IC). 2009 , 2009, 59-64		
611	Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. 2009 , 41, 348-53		286

610	Transcriptional control of human adipose tissue blood flow. 2009 , 17, 681-8	28
609	Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions--a systematic review. 2009 , 10, 617-26	30
608	N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. 2009 , 42, 1500-3	7
607	Association between sleep-disordered breathing, aminoterminal pro-brain natriuretic peptide (NT-proBNP) levels and insulin resistance in morbidly obese young women. 2009 , 20, 174-81	13
606	The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. 2009 , 405, 1-7	38
605	The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. 2009 , 136, 193-9	9
604	B-type natriuretic peptide-guided management and outcome in patients with obesity and dyspnea--results from the BASEL study. 2009 , 158, 488-95	17
603	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. 2009 , 53, 1343-1382	187
602	[Urinary levels of B-type natriuretic peptide (BNP) and ventricular systolic dysfunction in heart failure patients]. 2009 , 209, 168-75	1
601	Impact of atrial fibrillation on NT-proBNP levels in a 75-year-old population. 2009 , 69, 579-84	5
600	Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. 2009 , 207, 298-303	36
599	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. 2009 , 53, e1-e20	1224
598	Natriuretic peptides: physiologic and analytic considerations. 2009 , 5, 471-87	45
597	Role of obesity in cardiomyopathy and pulmonary hypertension. 2009 , 30, 509-23, ix	34
596	Hypertension: reflections on risks and prognostication. 2009 , 93, 541-58, Table of Contents	52
595	[NT-proBNP in practice: from chemistry to medicine]. 2009 , 67, 255-71	8
594	Association between perceived stress and plasma B-type natriuretic peptide concentrations. 2009 , 73, 1055-61	1
593	Heart failure with preserved ejection fraction. 2009 , 73, 404-10	46

592	Place des marqueurs biologiques en cardiologie. 2010 , 5, 1-10	
591	Is there a relationship between obesity, heart rate variability and inflammatory parameters in heart failure?. 2010 , 11, 118-24	10
590	Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy. 2010 , 28, 1638-45	9
589	Relationship between obesity and N-terminal brain natriuretic Peptide level as a prognostic value after acute myocardial infarction. 2010 , 40, 558-64	4
588	Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. 2009 , 118, 231-40	26
587	Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study. 2010 , 57, 727-33	30
586	Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. 2010 , 267, 119-29	48
585	Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. 2010 , 334, 53-65	11
584	Natriuretic pro-peptides in idiopathic intracranial hypertension. 2010 , 164, 71-7	10
583	Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease. 2010 , 165, 210-7	52
582	Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. 2010 , 105, 1570-6	33
581	Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. 2010 , 106, 1450-5	44
580	Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. 2010 , 268, 338-47	34
579	Natriuretic peptides: An overview for the clinician. 2010 , 5, 338-343	2
578	N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population. 2010 , 40, 645-50	5
577	The influence of diabetes on the relationship between N-terminal pro-B-type natriuretic peptide and body mass index. 2010 , 38, 1737-48	5
576	Gender dimorphic associations between N-terminal pro-brain natriuretic peptide, body mass index and blood pressure in children and adolescents. 2010 , 73, 341-8	13
575	Arterial stiffness: a brief review. 2010 , 31, 1267-76	175

574	Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. 2010 , 172, 190-6	42
573	NT-Pro-B-Type Natriuretic Peptide Levels in Infants with Failure to Thrive due to Caloric Deprivation. 2010 , 2010, 983468	2
572	Oxidative Stress and Heart Failure. 2010 , 221-242	
571	Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. 2010 , 12, 958-65	20
570	Lipid mobilization in subcutaneous adipose tissue during exercise in lean and obese humans. Roles of insulin and natriuretic peptides. 2010 , 299, E258-65	22
569	Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. 2010 , 7, 13-20	53
568	Use of biomarkers in evaluation of patients with heart failure. 2010 , 164, 88-117	2
567	Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. 2010 , 151, 5218-25	45
566	Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. 2010 , 56, 633-41	31
565	The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. 2010 , 151, 3665-74	34
564	Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients. 2010 , 140, 336-43	10
563	Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. 2010 , 143, 124-9	11
562	Le peptide natriurétique type B (BNP) chez les insuffisants cardiaques tunisiens. 2010 , 25, 171-178	
561	Visceral fat is negatively associated with B-type natriuretic peptide levels in patients with advanced type 2 diabetes. 2010 , 89, 174-80	16
560	Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. 2010 , 392, 100-5	40
559	The effect of nutrition on blood pressure. 2010 , 30, 365-401	139
558	Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. 2010 , 123, 646-51	150
557	Age and gender differences in the association between Nt-proBNP and glucometabolic disturbances. 2011 , 45, 294-300	1

556	Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. 2011 , 57, 1386-95	57
555	Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. 2011 , 58, 1119-25	51
554	The effect of obesity on chronic kidney disease. 2011 , 21, 66-71	41
553	Decreased plasma B-type natriuretic peptide levels in obesity are not explained by altered left ventricular hemodynamics. 2011 , 5, e267-360	3
552	The Use of Biomarkers in the Evaluation of Heart Failure. 2011 , 545-559	1
551	Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. 2011 , 410, 398-403	25
550	The natriuretic peptide system as a possible therapeutic target for stress-induced obesity. 2011 , 76, 388-90	3
549	Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?. 2011 , 22, 404-11	36
548	B-type natriuretic peptide and anthropometric measures in a Brazilian elderly population with a high prevalence of Trypanosoma cruzi infection. 2011 , 32, 1787-92	6
547	Natriuretic Peptides in Severe Aortic Stenosis - Role in Predicting Outcomes and Assessment for Early Aortic Valve Replacement. 2011 ,	
546	Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. 2011 , 7, 247-56	20
545	Natriuretic peptides in children: physiology and clinical utility. 2011 , 23, 452-9	3
544	Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. 2011 , 50, 1143-7	14
543	Elevated plasma levels of adropin in heart failure patients. 2011 , 50, 1523-7	50
542	In hemodialysis, adiponectin, and pro-brain natriuretic peptide levels may be subjected to variations in body mass index. 2011 , 15, 477-84	10
541	Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. 2011 , 108, 1564-9	11
540	Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation. 2011 , 30, 217-25	14
539	B-type natriuretic peptide increases after gastric bypass surgery and correlates with weight loss. 2011 , 25, 2338-43	35

538	Plasma B-type natriuretic peptide (BNP) variation in multi-trauma patients. 2011 , 83, 202-209		
537	Diagnostic and prognostic value of brain natriuretic peptide (BNP) concentrations in very elderly heart disease patients: specific geriatric cut-off and impacts of age, gender, renal dysfunction, and nutritional status. 2011 , 52, 106-10		17
536	Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. 2011 , 96, 3242-9		114
535	Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. 2011 , 13, 154-62		10
534	An initial characterization of N-terminal-proatrial natriuretic peptide in serum of Sprague Dawley rats. 2011 , 120, 262-8		13
533	Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. <i>Circulation</i> , 2011 , 124, 1021-7	16.7	40
532	Elevated pro-brain natriuretic peptide, troponin T and malnutrition inflammatory score in chronic hemodialysis patients with overt cardiovascular disease. 2011 , 117, c198-205		9
531	N-terminal pro-B-type natriuretic peptide in early and advanced phases of obesity. 2011 , 49, 1539-45		3
530	Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction. 2011 , 97, 551-6		20
529	Relationship of brain natriuretic peptide with metabolic syndrome parameters: an observational study. 2011 , 11, 678-84		2
528	Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. 2011 , 8, e1001112		79
527	Cardiac natriuretic peptides: contributors to cardiac cachexia or possible anti-obesity agents or both?. 2012 , 61, 2403-4		8
526	Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males. 2012 , 21, 513-22		14
525	Brain natriuretic peptide in term pregnancy. 2012 , 19, 520-5		13
524	Obesity in Older Adults: Epidemiology and Implications for Disability and Disease. 2012 , 22, 10-34		88
523	Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. 2012 , 58, 1673-81		124
522	Paradoxical clearance of natriuretic peptide between pulmonary and systemic circulation: a pulmonary mechanism of maintaining natriuretic peptide plasma concentration in obese individuals. 2012 , 97, E14-21		6
521	Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. 2012 , 97, 638-45		105

520	Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. 2012 , 14, 1240-8	26
519	Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study. 2012 , 35, 2510-4	23
518	Pediatric Metabolic Syndrome. 2012 ,	5
517	Is there a role for N-terminal probrain-type natriuretic peptide in determining volume status in haemodialysis patients?. 2012 , 122, 33-7	19
516	Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study. 2012 , 2012, 815098	12
515	The secret life of fat suggests new therapeutic targets. 2012 , 110, 1049-51	1
514	Does the relationship between natriuretic hormones and diastolic function differ by race?. 2012 , 344, 96-9	2
513	Contribution of extracardiac factors to the inconsistency between plasma B-type natriuretic peptide levels and the severity of pulmonary congestion on chest X-rays in the diagnosis of heart failure. 2012 , 51, 239-48	14
512	Peripheral signalling involved in energy homeostasis control. 2012 , 25, 223-48	45
511	Comment interpréter les biomarqueurs dans la démarche diagnostique?. 2012 , 53-59	
510	Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. 2012 , 20, 1511-8	22
509	NT-proBNP is associated with fibulin-1 in Africans: the SAfrEIC study. 2012 , 222, 216-21	17
508	Marked decrease in BNP levels in 2 related patients with reversible dilated cardiomyopathy. 2012 , 5, e65-e68	1
507	Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. 2012 , 33, 2001-6	176
506	Effects of chronic elevation of atrial natriuretic peptide and free fatty acid levels in the induction of type 2 diabetes mellitus and insulin resistance in patients with mitral valve disease. 2012 , 22, 58-65	7
505	Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. 2012 , 110, 870-6	157
504	Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension. 2012 , 110, 909-14	9
503	The natriuretic peptides and fat metabolism. 2012 , 367, 377-8	52

502	Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 2012 , 164, 763-770.e3	77
501	Obesity as an independent risk for left ventricular diastolic dysfunction in 692 Japanese patients. 2012 , 6, e175-262	6
500	The Relationship of Childhood Obesity with Cardiomyopathy and Heart Failure. 2012 , 199-215	3
499	Acarbose treatment enhances mid-regional pro-atrial natriuretic peptide concentrations in non-diabetic individuals: further evidence for a common cardiometabolic pathway?. 2012 , 55, 3392-5	5
498	Betaine and secondary events in an acute coronary syndrome cohort. 2012 , 7, e37883	45
497	Biomarkers and cardiovascular risk assessment for primary prevention: an update. 2012 , 58, 72-82	64
496	B-type natriuretic peptides in acute coronary syndromes: implications in an aging population. 2012 , 35, 682-5	4
495	Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity?. 2012 , 97, E731-9	68
494	Impact of obesity on plasma B-type natriuretic peptide levels in Japanese community-based subjects. 2012 , 27, 287-94	15
493	Kardiale Dyspnoe. 2012 , 9, 262-270	
492	Fasting long-acting natriuretic peptide correlates inversely with metabolic syndrome in kidney transplant patients. 2012 , 44, 646-50	7
491	Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection. 2012 , 19, 327-31	13
490	Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution. 2012 , 11, 22	10
489	The paradox of low BNP levels in obesity. 2012 , 17, 81-96	93
488	Inverse association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients. 2013 , 5, 19	8
487	Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies. 2013 , 28, 393-404	16
486	A genetic variant of the atrial natriuretic peptide gene is associated with left ventricular hypertrophy in a non-diabetic population--the Malmö preventive project study. 2013 , 14, 64	8
485	Morbid obesity: obscuring the diagnosis of aortic stenosis in a patient with cardiogenic wheezing. 2013 , 28, 155-9	1

484	Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. 2013 , 10, 190-7	17
483	Novel biomarkers for heart failure. 2013 , 11, 1155-69	18
482	N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes. 2013 , 28, 151-6	11
481	Gastric bypass surgery elevates NT-ProBNP levels. 2013 , 23, 1421-6	24
480	New biomarkers and heart failure. 2013 , 55, e345-e354	4
479	B-type natriuretic peptide is not a volume marker among patients on hemodialysis. 2013 , 28, 3082-9	33
478	Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. 2013 , 15, 859-67	49
477	Strategies for Management of Acute Decompensated Heart Failure. 2013 , 281-306	
476	Natriuretic peptides and cGMP signaling control of energy homeostasis. 2013 , 304, H358-68	85
475	Natriuretic peptides in heart failure. 2013 , 55, e370-e376	4
474	Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. 2013 , 62, 752-60	79
473	C-type natriuretic peptide plasma levels are reduced in obese adolescents. 2013 , 50, 50-4	9
472	Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. 2013 , 1, 345-352	28
471	Plasma MR-proANP levels are associated with carotid intima-media thickness in the general community: the KORA F4 study. 2013 , 230, 235-41	14
470	Low serum long-acting natriuretic peptide level correlates with metabolic syndrome in hypertensive patients: a cross-sectional study. 2013 , 44, 215-20	11
469	The way to a man's stomach is through his heart? the relation between natriuretic peptide levels and adipose tissue distribution. 2013 , 62, 761-2	1
468	Psychosocial correlates of atrial natriuretic peptide: a marker of vascular health. 2013 , 45, 99-109	4
467	Insulin signalling mechanisms for triacylglycerol storage. 2013 , 56, 949-64	156

466	A gut-heart connection in cardiometabolic regulation. 2013 , 19, 534-6		17
465	Regulation of metabolism by cGMP. 2013 , 140, 81-91		25
464	Peli1 sets the CNS on fire. 2013 , 19, 536-8		7
463	Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. 2013 , 34, 886-893c		175
462	Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome. 2013 , 98, 4882-9		15
461	Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. 2013 , 7, 139-46		5
460	Nutrition and Blood Pressure. 2013 , 415-443		
459	Association of plasma B-type natriuretic peptide concentrations with longitudinal blood pressure tracking in African Americans: findings from the Jackson Heart Study. 2013 , 61, 48-54		12
458	Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. <i>Circulation</i> , 2013 , 127, 509-16; discussion 516	16.7	45
457	NH2-terminal pro-brain natriuretic peptide and risk of diabetes. 2013 , 62, 3189-93		75
456	The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. 2013 , 36, 2850-6		42
455	Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. 2013 , 62, 147-53		45
454	Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. 2013 , 78, 783-9		32
453	Determination of the B-type natriuretic peptide level as a criterion for abnormalities in Japanese individuals in routine clinical practice: the J-ABS Multi-Center Study (Japan Abnormal BNP Standard). 2013 , 52, 171-7		25
452	Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. 2013 , 345, 211-7		19
451	Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure. 2013 , 8, e79096		12
450	Fat oxidation, hormonal and plasma metabolite kinetics during a submaximal incremental test in lean and obese adults. 2014 , 9, e88707		26
449	Cardiac Biomarkers. 2014 ,		3

448	Plasma natriuretic peptides in children and adolescents with obstructive sleep apnea and their changes following intervention. 2014 , 2, 22	4
447	Can low brain-derived neurotrophic factor levels be a marker of the presence of depression in obese women?. 2014 , 10, 2079-86	9
446	Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. 2014 , 1, 24	18
445	Coordinate control of adipose 'browning' and energy expenditure by Adrenergic and natriuretic peptide signalling. 2014 , 4, S17-20	14
444	The increasing impact of a higher body mass index on the decrease in plasma B-type natriuretic peptide levels. 2014 , 4, 39-46	4
443	Gestational diabetes mellitus and cardiovascular risk after pregnancy. 2014 , 10, 91-108	65
442	Catheter ablation of atrial fibrillation: on the pathophysiology of the arrhythmia and the impact of cardiac risk factor management. 2014 , 64, 2232-4	2
441	Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. 2014 , 44, 303-8	63
440	[Essential cardiac biomarkers in myocardial infarction and heart failure]. 2014 , 39, 727-39; quiz 740-1	1
439	N-terminal pro-B-type natriuretic peptide is inversely associated with metabolic syndrome in hypertensive patients. 2014 , 348, 210-4	6
438	B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. 2014 , 15, 122-34	35
437	Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. 2014 , 37, 138-45	7
436	Testosterone therapy improves the heart rate turbulence without effect on NT-proBNP level in men with metabolic syndrome. 2014 , 46, 116-9	2
435	Adipose Tissue and Adipokines in Health and Disease. 2014 ,	5
434	Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator. 2014 , 37, 801-8	22
433	Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome. 2014 , 8, 227-31	2
432	Biomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment?. 2014 , 22, 115-21	7
431	Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. 2014 , 57, 935-9	14

430	Overweight is associated with improved survival and outcomes in patients with atrial fibrillation. 2014 , 103, 533-42	33
429	Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. 2014 , 13, 36	48
428	Serum atrial natriuretic peptide level inversely associates with metabolic syndrome in older adults. 2014 , 14, 640-6	6
427	Biomarkers in adult congenital heart disease heart failure. 2014 , 10, 43-56	15
426	Obesity and Cardiovascular Disease. 2014 , 285-294	
425	Natriuretic peptides in cardiometabolic regulation and disease. 2014 , 11, 403-12	119
424	A heart-adipose tissue connection in the regulation of energy metabolism. 2014 , 10, 157-63	88
423	Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. 2014 , 144, 12-27	89
422	Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men. 2014 , 27, 620-7	16
421	B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. 2014 , 64, 1789-97	20
420	Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. <i>Circulation</i> , 2014 , 130, 1676-83	16.7 128
419	Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. 2014 , 37, 2899-908	85
418	Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. 2014 , 176, 611-7	153
417	The pathophysiology of heart failure with preserved ejection fraction. 2014 , 11, 507-15	353
416	Adverse reactions to biologic agents and their medical management. 2014 , 10, 612-27	63
415	Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. 2014 , 57, 1257-67	54
414	Perioperative fluid guidance with transthoracic echocardiography and pulse-contour device in morbidly obese patients. 2014 , 24, 2117-25	14
413	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). 2014 , 73, 684-90	23

412 10. Natriuretic peptides. **2014**, 181-194

411	Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients. 2014 , 40, 251-7	24
410	Association between serum soluble corin and obesity in Chinese adults: a cross-sectional study. 2015 , 23, 856-61	19
409	Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study). 2015 , 38, 1404-9	5
408	Natriuretic Peptides and Cardiometabolic Health. 2015 , 79, 1647-55	51
407	Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome. 2015 , 129, 933-49	50
406	[Measurement of natriuretic peptides in heart failure: the good laboratory and clinical practice]. 2015 , 156, 1235-45	1
405	Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients. 2015 , 33, 1215-25	21
404	Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis. 2015 , 33, 966-74	15
403	Different implication of elevated B-type natriuretic peptide level in patients with heart failure with preserved ejection fraction and in those with reduced ejection fraction. 2015 , 32, 623-9	3
402	Targeting fatty acid metabolism to improve glucose metabolism. 2015 , 16, 715-57	92
401	Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. 2015 , 33, 1458-64	28
400	Brain Natriuretic Peptide Clearance in Patients with Obesity and Insulin Resistance - a Mechanistic Study. 2015 , 5,	
399	Natriuretic peptides, obesity and cardiovascular diseases. 2015 , 61, 19-20	
398	Identifying biomarker patterns and predictors of inflammation and myocardial stress. 2015 , 21, 439-45	5
397	Atrial natriuretic peptide and aldosterone synthase gene in essential hypertension: a case-control study. 2015 , 567, 92-7	6
396	Diagnosis and Management of Pulmonary Hypertension. 2015 ,	
395	Gender-related alterations in plasma adrenomedullin level and its correlation with body weight gain. 2015 , 4, 43-9	15

394	Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. 2015 , 4,	40
393	Untreated diabetes mellitus, but not impaired fasting glucose, is associated with increased left ventricular mass and concentric hypertrophy in an elderly, healthy, Swedish population. 2015 , 9, 39-47	5
392	New insight into improvement of cardiovascular outcomes with intensive glycemic control in patients with metabolic syndrome and type 2 diabetes mellitus included. 2015 , 71, 9-15	
391	The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. 2015 , 17, 7	19
390	Weight loss, saline loading, and the natriuretic peptide system. 2015 , 4, e001265	29
389	Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). 2015 , 569, 1-6	98
388	Soluble ST2 in Ventricular Dysfunction. 2015 , 69, 139-59	4
387	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. 2015 , 116, 1304-10	3
386	Association of N-terminal pro-brain natriuretic peptide and hemodynamic parameters measured by impedance cardiography in patients with essential hypertension. 2015 , 37, 148-54	1
385	Reduced carotid baroreceptor distensibility-induced baroreflex resetting contributes to impairment of sodium regulation in rats fed a high-fat diet. 2015 , 308, H942-50	4
384	Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. 2015 , 3, 513-519	51
383	Angiotensin II Receptor Blocker Nephilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. 2015 , 22, 241-6	15
382	Serial ST2 testing in hospitalized patients with acute heart failure. 2015 , 115, 32B-7B	26
381	Patient selection in heart failure with preserved ejection fraction clinical trials. 2015 , 65, 1668-1682	89
380	N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. 2015 , 28, 1262-6	24
379	Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. 2015 , 29, 313-21	11
378	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. 2015 , 116, 991-1006	571
377	An Emerging Role of Natriuretic Peptides: Igniting the Fat Furnace to Fuel and Warm the Heart. 2015 , 90, 1666-78	12

376	Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. 2015 , 4, e001544	70
375	Defective Natriuretic Peptide Receptor Signaling in Skeletal Muscle Links Obesity to Type 2 Diabetes. 2015 , 64, 4033-45	56
374	Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population. 2015 , 38, 74-9	9
373	The association between daily physical activity and plasma B-type natriuretic peptide in patients with glucose intolerance: a cross-sectional study. 2015 , 5, e006276	16
372	INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. 2015 , 4, R25-36	23
371	ANP-ing Up Diabetes: Impaired Natriuretic Peptide Action in Muscle Forms a Mechanistic Link Between Obesity and Diabetes. 2015 , 64, 3978-80	1
370	The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. 2015 , 62, 841-7	28
369	Galectin-3 and heart failure: prognosis, prediction & clinical utility. 2015 , 443, 48-56	46
368	Beneficial Effects of Combined AT1 Receptor/Nepriylsin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye. 2016 , 57, 6722-6730	9
367	Correlation between B type natriuretic peptide and metabolic risk factors. 2016 , 12, 334-40	8
366	Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. 2016 , 8, 35-45	14
365	A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease. 2016 , 12, 85-103	47
364	Biomarkers of cardiovascular stress in obstructive sleep apnea. 2016 , 460, 152-63	17
363	Heart failure - what the general physician needs to know. 2016 , 16, 303	1
362	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. 2016 , 34, 1678-88	8
361	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. 2016 , 92, 346-55	5
360	Molecular Physiology of Membrane Guanylyl Cyclase Receptors. 2016 , 96, 751-804	182
359	Impact of Protein Nutritional Status on Plasma BNP in Elderly Patients. 2016 , 20, 937-943	4

358	Regulation of B-type natriuretic peptide synthesis by insulin in obesity in male mice. 2016 , 101, 113-23	7
357	B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. 2016 , 150, 102-11	15
356	Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. 2016 , 21, 538-43	5
355	Computerized tomography measured liver fat is associated with low levels of N-terminal pro-brain natriuretic protein (NT-proBNP). Multi-Ethnic Study of Atherosclerosis. 2016 , 65, 728-735	5
354	The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. 2016 , 37, 2869-2878	144
353	ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss. 2016 , 65, 935-43	15
352	Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-nepriylsin inhibition compared with AT1 receptor blockade alone. 2016 , 130, 1209-20	28
351	Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. 2016 , 5,	55
350	Association between N-terminal pro-brain natriuretic peptide and adiponectin in healthy Japanese men. 2016 , 460, 138-41	7
349	Association of cardiac NT pro-B-type natriuretic peptide with metabolic and endothelial risk factors in young obese hypertensive patients: a perspective on the hypothalamic pituitary adrenal axis activation. 2016 , 8, 52	3
348	Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study. 2016 , 65, 1489-97	22
347	Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. 2016 , 24, 820-8	53
346	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 134, e535-e578	16.7 164
345	Brain Natriuretic Peptide and Body Fluid Composition in Patients with Chronic Kidney Disease: A Cross-Sectional Study to Evaluate the Relationship between Volume Overload and Malnutrition. 2016 , 6, 337-46	14
344	Obesity paradox in heart failure: a heavy matter. 2016 , 3, 227-234	45
343	Targeting cardiac natriuretic peptides in the therapy of diabetes and obesity. 2016 , 20, 1445-1452	28
342	Potent influence of obesity on suppression of plasma B-type natriuretic peptide levels in patients with acute heart failure: An approach using covariance structure analysis. 2016 , 215, 283-90	19
341	The influence of body composition on the N-terminal pro-B-type natriuretic peptide level and its prognostic performance in patients with acute coronary syndrome: a cohort study. 2016 , 15, 58	7

340	Pharmacologic Trends of Heart Failure. 2016,		
339	Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional study. 2016, 15, 3		6
338	Statin treatment is associated with a negative correlation between NT-proBNP and insulin resistance in patients without history of heart failure. 2016, 459, 84-88		1
337	The evaluation of brain natriuretic peptide changes and difficult airway predictors during perioperative period of pregnancy. 2016, 185, 59-62		
336	Natriuretic peptide control of energy balance and glucose homeostasis. 2016, 124, 84-91		36
335	Observational Study of Obstructive Sleep Apnea in Wake-Up Stroke: The SLEEP TIGHT Study. 2016, 41, 233-41		26
334	A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. 2016, 67, 330-7		35
333	Impact of alcohol intake on the relationships of uric acid with blood pressure and cardiac hypertrophy in essential hypertension. 2016, 68, 447-454		5
332	Acute Metabolic Influences on the Natriuretic Peptide System in Humans. 2016, 67, 804-812		23
331	Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. 2016, 24, 287-95		27
330	Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management. 2016, 16, 641-50		9
329	LXR improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. 2016, 59, 634-43		26
328	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2016, 133, 631-8	16.7	69
327	A novel peptide adropin in cardiovascular diseases. 2016, 453, 107-13		25
326	Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial. 2016, 47, 523-6		31
325	The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure. 2016, 65, 38-47		19
324	New Pharmacological Strategies to Increase cGMP. 2016, 67, 229-43		26
323	Facing Morbid Obesity: How to Approach It. 2016, 67, 391-7		11

322	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. 2017 , 10,	9
321	Paracrine cross-talk between skeletal muscle and macrophages in exercise by PGC-1 β -controlled BNP. 2017 , 7, 40789	17
320	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. 2017 , 19, 19	12
319	Inverse Correlation of Venous Brain Natriuretic Peptide Levels with Body Mass Index Is due to Decreased Production. 2017 , 137, 159-166	5
318	The multifaceted role of natriuretic peptides in metabolic syndrome. 2017 , 92, 826-835	35
317	Does Insulin Resistance Trigger Natriuretic Peptide Deficiency?. 2017 , 17, 11-12	4
316	Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism. 2017 , 6, 276-287	13
315	Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. 2017 , 106, 401-410	10
314	Early 24-hour blood pressure response to Roux-en-Y gastric bypass in obese patients. 2017 , 77, 53-59	9
313	Assessment of left atrial volume and function by real time three-dimensional echocardiography in obese patients. 2017 , 34, 210-216	6
312	Second messenger signaling mechanisms of the brown adipocyte thermogenic program: an integrative perspective. 2017 , 31,	13
311	Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). <i>Circulation</i> , 2017 , 136, 1588-1597	16.7 163
310	Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. 2017 , 10,	53
309	Serum proatrial natriuretic peptide does not increase with higher systolic blood pressure in obese men. 2017 , 103, 154-158	4
308	Natriuretic peptides in the control of lipid metabolism and insulin sensitivity. 2017 , 18, 1243-1259	22
307	Effect of bariatric surgery on heart failure. 2017 , 15, 567-579	17
306	N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. 2017 , 7, 5810	11
305	Hemodynamic Determinants of the Biologic Variation of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure. 2017 , 23, 835-842	2

304	The Effects of Bariatric Surgery on the Cardiovascular System. 2017 , 11, 1	
303	Short sleep duration is associated with B-type natriuretic peptide levels and predicts the death of Japanese patients with type 2 diabetes. 2017 , 36, 1-5	4
302	Processing-independent proANP measurement for low concentrations in plasma: reference intervals and effect of body mass index and plasma glucose. 2017 , 56, 132-137	1
301	Modulation of natriuretic peptide receptors in human adipose tissue: molecular mechanisms behind the "natriuretic handicap" in morbidly obese patients. 2017 , 186, 52-61	13
300	Differences in Natriuretic Peptide Levels by Race/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis). 2017 , 120, 1008-1015	33
299	Determinants of low levels of brain natriuretic peptide in morbid obesity. 2017 , 36, 1075-1081	10
298	Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction. 2017 , 227, 272-277	42
297	Plasma levels of atrial and brain natriuretic peptides in apparently healthy subjects: Effects of sex, age, and hemoglobin concentration. 2017 , 228, 599-604	15
296	Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. 2017 , 101, 254-263	58
295	Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center. 2017 , 183, 40-48	10
294	Factors influencing brain natriuretic peptide levels in healthy pregnant women. 2017 , 228, 749-753	18
293	Obesity: A Perspective from Hypertension. 2017 , 101, 139-157	29
292	Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". 2017 , 2, 770-789	96
291	Genome-Wide Association Study Implicates Atrial Natriuretic Peptide Rather Than B-Type Natriuretic Peptide in the Regulation of Blood Pressure in the General Population. 2017 , 10,	15
290	The emerging role of new biomarkers of congestion in heart failure. 2017 , 2, 24-24	1
289	NT-proBNP, Cardiometabolic Risk Factors, and Nutritional Status in Hemodialysis Patients. 2017 , 2017, 1312547	3
288	Cardiokines as Modulators of Stress-Induced Cardiac Disorders. 2017 , 108, 227-256	18
287	NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study. 2017 , 16, 119	15

286	Cardiac Hypertrophy and Brain Natriuretic Peptide Levels in an Ovariectomized Rat Model Fed a High-Fat Diet. 2017 , 23, 380-391		8
285	Usefulness of amino terminal pro-B-type natriuretic peptide in evaluating children with cardiac failure. 2017 , 7, 380-388		3
284	Predictors of 10-year changes in levels of N-terminal pro B-type natriuretic peptide and cardiac troponin I in the elderly. 2018 , 257, 300-305		7
283	Obese Hypertensive Men Have Lower Circulating Proatrial Natriuretic Peptide Concentrations Despite Greater Left Atrial Size. 2018 , 31, 645-650		8
282	Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 2018 , 7,		7
281	Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. 2018 , 20, 873-878		25
280	Impact of body mass index on mortality and hospitalisation of patients with atrial fibrillation. 2018 , 17, 627-636		6
279	Increased Levels of Cardiac Troponin I in Subjects with Extremely Low B-type Natriuretic Peptide Levels. 2018 , 8, 5120		11
278	Leptin-Aldosterone-Nephrilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. <i>Circulation</i> , 2018 , 137, 1614-1631	16.7	105
277	Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. 2018 , 8, 1097		22
276	Obesity and heart failure with preserved ejection fraction: A growing problem. 2018 , 28, 322-327		12
275	Obesity and the Obesity Paradox in Heart Failure. 2018 , 546-564		
274	Brown Adipose Tissue and Body Weight Regulation. 2018 , 117-132		2
273	Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. 2018 , 7, 115-123		10
272	Do Most Obese People with Exercise Intolerance and a Normal Ejection Fraction Have Treatable Heart Failure?. 2018 , 131, 863-864		7
271	Correlation of plasma B-type natriuretic peptide levels with metabolic risk markers. 2018 , 151, 481-486		1
270	Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Nephrilysin, and Sodium-Glucose Cotransporter-2. 2018 , 6, 633-639		80
269	Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure. 2018 , 258, 165-171		11

268	Brain natriuretic peptide levels in middle aged subjects with normal left ventricular function in relation to mild-moderate COPD. 2018 , 12, 1061-1067	
267	Novel Parameter to Predict Left Ventricular Filling Pressure: Product of Log B-Type Natriuretic Peptide and Ratio of Mitral Inflow Early and Late Diastolic Filling Velocities. 2018 , 24, 29-32	3
266	Do estrogens enhance activation of brown and beige adipose tissues?. 2018 , 187, 24-31	24
265	Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2018 , 3, 11-17	33
264	Natriuretic Peptide Deficiency-When There Is Too Little of a Good Thing. 2018 , 3, 7-9	14
263	Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. 2018 , 14, 13-25	53
262	Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. 2018 , 5, 53-62	10
261	Regulation of circulating chromogranin B levels in heart failure. 2018 , 23, 78-87	3
260	Correlation of plasma B-type natriuretic peptide levels with metabolic risk markers. 2018 , 151, 481-486	
259	Accuracy of B-natriuretic peptide for the diagnosis of decompensated heart failure in muscular dystrophies patients with chronic respiratory failure. 2018 , 10, 7917	2
258	Atrial Natriuretic Factor and the Family of Natriuretic Peptides. 2018 , 569-580	
257	Oxidative Stress and Heart Failure. 2018 , 230-251	3
256	(Pro)Renin receptor mediates obesity-induced antinatriuresis and elevated blood pressure via upregulation of the renal epithelial sodium channel. 2018 , 13, e0202419	13
255	Brain Natriuretic Peptide in Plasma as Predictor of All-Cause Mortality in a Large Danish Primary Health Care Population Suspected of Heart Failure. 2018 , 64, 1723-1731	7
254	Diabetes mellitus and heart failure: insights from a toxic relationship. 2018 , 35, 112-116b	
253	Smoking modifies the effect of two independent SNPs rs5063 and rs198358 of NPPA on central obesity in the Chinese Han population. 2018 , 97, 987-994	0
252	Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function. 2018 , 50, 913-928	20
251	Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP. 2018 , 17, 120	14

250	Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management. 2018 , 72, 270-276	30
249	N-Terminal Brain Natriuretic Peptide First Week After Burn Injury. 2018 , 39, 805-810	
248	Heart Failure. 2018 , 168, ITC81-ITC96	5
247	Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. 2018 , 3, 883-887	6
246	Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. 2018 , 93, 980-990	4
245	Patient-Centered Approach for Hypertension Management in End-Stage Kidney Disease: Art or Science?. 2018 , 38, 355-368	
244	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. 2018 , 103, 2522-2533	4
243	The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers. 2018 , 15, 239-249	12
242	[Heart or lung? : Diagnostics and management of unclear exertional dyspnea]. 2018 , 43, 567-582	
241	Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. 2018 , 46, 3017-3029	11
240	Acute effects of insulin on circulating natriuretic peptide levels in humans. 2018 , 13, e0196869	5
239	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. 2018 , 3, 1000-1005	24
238	Dry weight targeting: The art and science of conventional hemodialysis. 2018 , 31, 551-556	15
237	Impact of underlying heart disease per se on the utility of preoperative NT-proBNP in adult cardiac surgery. 2018 , 13, e0192503	6
236	Renal Clearance of N-Terminal pro-Brain Natriuretic Peptide Is Markedly Decreased in Chronic Kidney Disease. 2019 , 1, 326-332	3
235	Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. 2019 , 6, 110	16
234	Herz oder Lunge?. 2019 , 16, 9-21	
233	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. 2019 , 94, 1199-1209	35

232	Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease. 2019 , 20,	23
231	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology. 2019 , 32, 1379-1395.e2	6
230	Plasma proatrial natriuretic peptide associates with lipid oxidation during exercise and cardiorespiratory fitness in healthy young adults. 2019 , 122, 170156	2
229	Clinical predictors of acute hyponatremia following LARIAT ligation of the left atrial appendage. 2019 , 30, 2501-2507	2
228	Morbid Obesity as a Therapeutic Target for Heart Failure. 2019 , 21, 52	4
227	An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. 2019 , 19, 1019-1029	5
226	NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis. 2019 , 105, 1590-1596	2
225	How do diet and exercise programmes affect the cardiovascular risk profiles of obese children?. 2019 , 29, 200-205	2
224	Characterisation of N-terminal pro-brain natriuretic peptide in dialysis patients and its reduced prognostic significance in the elderly. 2019 , 9, 6630	4
223	Associations of Arterial Stiffness Indices With Measures of Insulin Resistance and Renal Sodium Reabsorption. 2019 , 32, 810-812	3
222	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. 2019 , 21, 715-731	193
221	MR-proANP Associated with Body Mass Index in Patients with Anorexia Nervosa. 2019 , 4, 132-134	1
220	Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. 2019 , 20,	12
219	70-year legacy of the Framingham Heart Study. 2019 , 16, 687-698	63
218	Race-based demographic, anthropometric and clinical correlates of N-terminal-pro B-type natriuretic peptide. 2019 , 286, 145-151	7
217	Obesity, kidney dysfunction and hypertension: mechanistic links. 2019 , 15, 367-385	171
216	Cardiac myocyte KLF5 regulates body weight via alteration of cardiac FGF21. 2019 , 1865, 2125-2137	6
215	Closing the Book on Androgens and Natriuretic Peptides. 2019 , 73, 1297-1299	2

214	Effect of Testosterone on Natriuretic Peptide Levels. 2019 , 73, 1288-1296	15
213	Relation of Obesity to Outcomes of Hospitalizations for Atrial Fibrillation. 2019 , 123, 1448-1452	8
212	Emerging concepts of receptor endocytosis and concurrent intracellular signaling: Mechanisms of guanylyl cyclase/natriuretic peptide receptor-A activation and trafficking. 2019 , 60, 17-30	12
211	Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study. 2019 , 108, 1371-1380	6
210	Association of Estimated Insulin Resistance with N-Terminal B-Type Natriuretic Peptide Concentration in Men with Metabolic Syndrome. 2019 , 2019, 8571795	
209	Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. 2019 , 9, 2045894019878599	11
208	Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. 2019 , 9, 19178	7
207	The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. 2019 , 21, 156-162	18
206	Biomarkers in Shortness of Breath. 2019 , 129-137	1
205	Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes. 2019 , 45, 429-435	7
204	Novel biomarkers of cardiovascular disease: Applications in clinical practice. 2019 , 56, 33-60	37
203	Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. 2019 , 280, 184-189	5
202	ADMA and NT pro-BNP are associated with overall mortality in elderly. 2019 , 49, e13041	4
201	Evaluation of cardiac status in children with intestinal failure on long-term parenteral nutrition. 2019 , 15, 42-45	
200	B-type natriuretic peptide levels and benign adiposity in obese heart failure patients. 2019 , 24, 219-226	1
199	Post-discharge rise in BNP and rehospitalization for heart failure. 2019 , 44, 450-454	3
198	Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men. 2019 , 111, 98-102	3
197	Postoperative B-Type Natriuretic Peptide as Predictor for Postoperative Outcomes in Patients Implanted With Left Ventricular Assist Devices. 2019 , 65, 148-151	3

196	Heart Hormones. 2020 , 327-340	2
195	Independent Impact of Gynoid Fat Distribution and Free Testosterone on Circulating Levels of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in Humans. 2019 , 9,	7
194	Are Obese Patients With Heart Failure Very Different From Non-Obese Patients?. 2020 , 26, 118-119	
193	Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. 2020 , 22, 214-227	27
192	Association between body mass index and mortality in atrial fibrillation patients with and without diabetes mellitus: Insights from a multicenter registry study in China. 2020 , 30, 2242-2251	2
191	Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study. 2020 , 19, 178	5
190	Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy. 2020 , 7, 4172	5
189	Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure. 2020 , 63, 649-655	4
188	The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. 2020 , 21,	11
187	NT-proBNP: Can We Better Utilize Biomarkers in Patients With Diabetes?. 2020 , 43, 2904-2905	2
186	Obesity, kidney dysfunction, and inflammation: interactions in hypertension. 2021 , 117, 1859-1876	16
185	The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries. 2020 , 18, 601-614	5
184	Accumulation of natriuretic peptides is associated with protein energy wasting and activation of browning in white adipose tissue in chronic kidney disease. 2020 , 98, 663-672	2
183	Effect of insulin on natriuretic peptide gene expression in porcine heart. 2020 , 131, 170370	
182	An Impaired Natriuretic Peptide Hormone System May Play a Role in COVID-19 Severity in Vulnerable Populations. 2020 , 2, 596	4
181	Protective Effects of a Discontinuous Treatment with Alpha-Lipoic Acid in Obesity-Related Heart Failure with Preserved Ejection Fraction, in Rats. 2020 , 9,	6
180	Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies. 2020 , 16, 357-368	11
179	Contentious role of 'Good Adiponectin' in pulmonary and cardiovascular diseases: Is adiponectin directed therapy a boon or a bane?. 2020 , 175, 106-119	

178	Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. 2020 , 126, 1477-1500	151
177	The Importance of Natriuretic Peptides in Cardiometabolic Diseases. 2020 , 4, bvaa052	13
176	Natriuretic peptides for heart failure screening in nursing homes: a systematic review. 2021 , 26, 1131-1140	1
175	N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis. 2020 , 2020, 9528014	0
174	Sex-related differences in contemporary biomarkers for heart failure: a review. 2020 , 22, 775-788	26
173	Evaluation and management of heart failure with preserved ejection fraction. 2020 , 17, 559-573	113
172	Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. 2020 , 25, 248-259	2
171	Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. 2020 , 132, 170352	4
170	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. 2020 , 7, 1201-1209	10
169	Gender-specific association between body mass index and all-cause mortality in patients with atrial fibrillation. 2020 , 43, 706-714	4
168	Atrial fibrillation in patients with heart failure with preserved ejection fraction. 2020 , 35, 260-270	1
167	Impact of Weight Loss with Laparoscopic Sleeve Gastrectomy on Left Ventricular Diastolic Function: a Prospective Study. 2020 , 30, 3280-3286	3
166	Deficient serum furin predicts risk of abdominal obesity: findings from a prospective cohort of Chinese adults. 2021 , 97, 234-238	7
165	The Effects of Salt and Glucose Intake on Angiotensin II and Aldosterone in Obese and Nonobese Patients with Essential Hypertension. 2020 , 2020, 6017105	3
164	Effects of Low-Energy Diet or Exercise on Cardiovascular Function in Working-Age Adults With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded End Point Trial. 2020 , 43, 1300-1310	18
163	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. 2021 , 35, 1839-1859	6
162	Effect of laparoscopic sleeve gastrectomy on vasoactive mediators in obese hypertensive patients: A prospective study. 2021 , 94, 193-203	2
161	High protein diet leads to prediabetes remission and positive changes in incretins and cardiovascular risk factors. 2021 , 31, 1227-1237	2

160 *Obesity et maladies cardiovasculaires. 2021, 263-267*

159 *Assessing congestion in acute heart failure using cardiac and lung ultrasound - a review. 2021, 19, 165-176* 3

158 *Diet-dependent Natriuretic Peptide Receptor C expression in adipose tissue is mediated by PPAR α via long-range distal enhancers.*

157 *Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism. 2021, 72, 882-892* 3

156 *Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. 2021, 52, 521-530* 8

155 *Alternative Echocardiographic Algorithm for Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction. 2021, 143, 80-88* 0

154 *Association between Visceral or Subcutaneous Fat Accumulation and B-Type Natriuretic Peptide among Japanese Subjects: A Cross-Sectional Study. 2021, 10,*

153 *Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults. 2021, 77, 980-992* 5

152 *Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. 2021, 9, 192-200* 8

151 *Natriuretic Peptides as Predictors of Protein-Energy Wasting in Hemodialysis Population. 2021,* 1

150 *Close Linkage Between Natriuretic Peptides and Obesity - Impact of Sex on the Interorgan Metabolic Crosstalk. 2021, 85, 655-656* 1

149 *Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. 2021, 77, 2291-2303* 4

148 *Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure. 2021, 11, 10096*

147 *A-lines and B-lines in patients with acute heart failure. 2021, 10, 909-917* 2

146 *Role of natriuretic peptides in the cardiovascular-adipose communication: a tale of two organs. 2021, 1* 3

145 *An Hypothesis: Disproportion Between Cardiac Troponin and B-Type Natriuretic Peptide Levels-A High Risk and Poor Prognostic Biomarker in Patients With Fulminant Myocarditis?. 2021, 30, 837-842* 2

144 *Six-year changes in N-terminal pro-brain natriuretic peptide and changes in weight and risk of obesity. 2021, 29, 1215-1222*

143 *Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. 2021, 27, 1231-1239* 0

142	Diagnostic Thresholds for Pre-Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population. 2021 , 10, e020447	4
141	Natriuretic Peptide Deficiency in Obese Individuals: Mechanistic Insights From Healthy Organ Donor Cohort. 2021 , 77, 3138-3140	3
140	Framingham Heart Study: JACC Focus Seminar, 1/8. 2021 , 77, 2680-2692	9
139	Cardiac natriuretic peptide deficiency sensitizes the heart to stress induced ventricular arrhythmias via impaired CREB signaling. 2021 ,	0
138	Intensive Lifestyle Intervention Increases Plasma Midregional Proatrial Natriuretic Peptide Concentrations in Overweight Children. 2021 , 10, e020676	1
137	B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels. 2021 , 11,	
136	Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study. 2021 , 10, 21	2
135	Cardiovascular Biomarkers of Obesity and Overlap With Cardiometabolic Dysfunction. 2021 , 10, e020215	1
134	Obesity and Heart Failure with Preserved Ejection Fraction. 2021 , 17, 345-356	1
133	Poor Masticatory Capacity and Blood Biomarkers of Elevated Cardiovascular Disease Risk in the Community: The Paris Prospective Study III. 2021 , 41, 2225-2232	2
132	Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo. 2021 , 11, 17466	6
131	Diet-dependent natriuretic peptide receptor C expression in adipose tissue is mediated by PPAR α via long-range distal enhancers. 2021 , 297, 100941	1
130	Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis. 2021 , 12, 693099	3
129	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. 2021 , 48, 101281	0
128	NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease. 2021 , 10,	0
127	Underweight Is Associated with Poor Prognosis in Heart Failure with Preserved Ejection Fraction. 2021 , 62, 1042-1051	0
126	The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium. 2021 , 12, 735070	2
125	Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease. 2021 , 8, 713191	1

124	Potential pitfalls when interpreting plasma BNP levels in heart failure practice. 2021 , 78, 269-274	2
123	Usefulness of cardiac hormones for evaluating valvular disease in cynomolgus monkeys (<i>Macaca fascicularis</i>). 2021 , 83, 716-723	0
122	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. 2020 , 22, 1551-1567	41
121	Use of Natriuretic Peptides in the Emergency Department and the ICU. 2009 , 523-530	0
120	Vasoactive Molecules and the Kidney. 2012 , 384-420	2
119	Cardiac natriuretic peptides. 2020 , 17, 698-717	95
118	B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study. 2021 , 67, 204-215	2
117	A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm. 2004 , 3, 171-6	18
116	Effect of Bariatric Surgery on Natriuretic Peptide Levels: A Systematic Review and Meta-Analysis. 2022 , 30, 8-15	2
115	Conjugated equine estrogens and estradiol benzoate differentially modulate the natriuretic peptide system in spontaneously hypertensive rats. 2013 , 20, 554-60	5
114	Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS. 2019 , 5,	7
113	Insulin receptor substrates differentially exacerbate insulin-mediated left ventricular remodeling. 2020 , 5,	8
112	Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. 2012 , 122, 1022-36	610
111	Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. 2012 , 122, 4675-9	127
110	Association of fat mass profile with natriuretic peptide receptor alpha in subcutaneous adipose tissue of medication-free healthy men: A cross-sectional study. 2018 , 7, 327	2
109	Impact of body mass index on plasma N-terminal ProB-type natriuretic peptides in Chinese atrial fibrillation patients without heart failure. 2014 , 9, e105249	6
108	Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension. 2015 , 10, e0117864	7
107	Short term variation in NTproBNP after lifestyle intervention in severe obesity. 2017 , 12, e0181212	12

106	Homoarginine-A prognostic indicator in adolescents and adults with complex congenital heart disease?. 2017 , 12, e0184333	6
105	A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA). 2017 , 12, e0189858	12
104	Biochemical markers after the Norseman Extreme Triathlon. 2020 , 15, e0239158	3
103	Importance of Basal Metabolic Index in the Diagnosis of Heart Failure With B-Type Natriuretic Peptide. 2019 , 10, 211-215	1
102	Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. 2005 , 46, 465-75	14
101	N-terminal pro-B-type natriuretic peptide level is depressed in patients with significant coronary artery disease who have high body mass index. 2008 , 49, 403-12	5
100	Usefulness of plasma BNP levels as a marker of left ventricular wall stress in obese individuals. 2009 , 50, 173-82	10
99	. 2018 , 58, 27-41	5
98	Brain Natriuretic Peptide in Liver Cirrhosis and Fatty Liver: Correlation with Cardiac Performance. 2016 , 8, 1984-93	9
97	Does impaired processing of pro-B-type (or brain) natriuretic peptide cause decreased plasma BNP levels in obese heart failure patients?. 2019 , 7, S221	5
96	Glycosylation of natriuretic peptides in obese heart failure: mechanistic insights. 2019 , 7, 611	6
95	Atrial Natriuretic Peptide Affects Stimulus-Secretion Coupling of Pancreatic ECells. 2017 , 66, 2840-2848	12
94	Obesity and Hypertension. 2006 , 33-50	1
93	Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. 2017 , 21, 1-150	17
92	Review Of Obesity And Atrial Fibrillation: Exploring The Paradox. 2015 , 8, 1259	5
91	Metabolic Crosstalk between the Heart and Fat. 2020 , 50, 379-394	4
90	Range of adiposity and cardiorenal syndrome. 2020 , 11, 322-350	7
89	Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study. 2020 , 15, 25	2

- 88 Plasma mid-regional pro-atrial natriuretic peptide predicts cardiovascular events in patients with type 2 diabetes independently of subclinical organ damage. **2021**, 182, 109095 0
- 87 Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study). **2021**, 15, 1487-1498 1
- 86 Biology of Natriuretic Peptides. **2006**, 347-372
- 85 Acute Heart Failure. **2006**, 203-226
- 84 Heart Failure and Obesity: The Risk of Development and the Treatment of Heart Failure in Obese Patients. **2006**, 403-428
- 83 Strategies for Management of Decompensated Heart Failure. **2007**, 385-409
- 82 Use of natriuretic peptide assay in dyspnea. **2008**, 105, 95-100 3
- 81 Use of Natriuretic Peptides in the Emergency Department and the ICU. **2009**, 523-530
- 80 Age, systolic blood pressure, hemoglobin level, the combination of BMI and percent body fat measured by bioelectrical impedance method, and under-nutrition influence the brain natriuretic peptide level. **2011**, 38, 517-523
- 79 Correlation of Urine Albumin/Creatinine Ratio (UACR), High Sensitivity C-Reactive Protein (hsCRP) and N-Terminal Pro Brain Natriuretic Peptide (NT-proBNP) with Atherosclerosis (OxLDL) in Centrally Obese Men. **2011**, 3, 37
- 78 Biomarkers in diastolic heart failure diagnosing. **2011**, 17, 305-315 1
- 77 The influence of visceral obesity on the N-terminal fragment of brain natriuretic peptide precursor (NT-proBNP) concentrations in hemodialysis patients. **2012**, 45, 467-474
- 76 Future studies should consider multiple predisposing conditions in predicting weaning failure from mechanical ventilation in patients after cardiac surgery. **2013**, 68, 725
- 75 The effect of age and NT-proBNP on the association of central obesity with 6-years cardiovascular mortality of middle-aged and elderly diabetic people: the population-based Casale Monferrato study. **2014**, 9, e96076 1
- 74 Approach to the Patient with Elevated Pulmonary Arterial Pressure. **2015**, 165-201
- 73 Diagnostic Testing and the Assessment of Heart Failure. **2015**, 31-45
- 72 Volume Assessment and Management: Medical and Device Therapies. **2016**, 125-163
- 71 Acute Decompensated Heart Failure: Treatment Guidelines. **2017**, 195-218 0

- 70 Biomarkers: New Horizon for Heart Failure Practice. **2018**, 17-38
- 69 OBSOLETE: Obesity and The Obesity Paradox in Heart Failure. **2018**,
- 68 Association of fat mass profile with natriuretic peptide receptor alpha in subcutaneous adipose tissue of medication-free healthy men: A cross-sectional study. **2018**, 7, 327 1
- 67 [Soluble ST2 - biomarker for prognosis and monitoring in decompensated heart failure]. **2019**, 59, 18-27 1
- 66 Obesidade e Fibrilaç o Atrial. **2020**, 32, 153-154
- 65 Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases. 6,
- 64 Heart Failure and Body Habitus: What Would Be the Confounding Factors of Outcome Prediction in Obese Patients with Heart Failure?. **2020**, 2, 66
- 63 N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. **2020**, 15, e0243213 1
- 62 Plasma Clearance of B-Type Natriuretic Peptide (BNP) before and after Bariatric Surgery for Morbid Obesity. **2021**, 67, 662-671 1
- 61 Role of expression of atrial natriuretic peptide gene in essential hypertension among Egyptian patients. **2021**, 57, 240-246
- 60 Nutrition and blood pressure. **2022**, 699-739
- 59 Obesity and Atrial Fibrillation. **2020**, 32, 153-154
- 58 The Impact of Body Mass Index on the Prognostic Value of N-Terminal proB-Type Natriuretic Peptide in Patients with Heart Failure: an Analysis from the Korean Heart Failure (KorHF) Registry. **2020**, 2, 45 2
- 57 Clinical Considerations and Applications in Cardiac Diseases. **2006**, 91-132 1
- 56 Obesity, Diabetes, and Hypertension. **2006**, 169-192 1
- 55 Natriuretic Peptides in the Diagnosis of Diastolic Heart Failure. **2008**, 175-185
- 54 The clinical biochemistry of obesity. **2004**, 25, 165-81 81
- 53 The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. **2007**, 1, 143-55

52	Differences in hypertension between blacks and whites: an overview. 2007 , 18, 241-7	47
51	Exploring The Obesity Paradox In Atrial Fibrillation. AFBAR (Atrial Fibrillation Barbanza Area) Registry Results. 2014 , 6, 991	7
50	ST2 and Galectin-3: Ready for Prime Time?. 2016 , 27, 238-52	15
49	Effects of an interdisciplinary weight loss program on fibroblast growth factor 21 and inflammatory biomarkers in women with overweight and obesity. 2021 , 65,	
48	The Role of ANP Level Response in Interdisciplinary Weight Loss Therapy on Cardiometabolic Risk and Body Composition in Adolescents with Obesity.. 2022 , 118, 33-40	
47	Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. 2021 ,	2
46	Epicardial adipose tissue as a mediator of cardiac arrhythmias. 2021 ,	2
45	Association of N-Terminal Pro-Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future Hypertension.. 2022 ,	0
44	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.. 2022 , 12, e12028	1
43	Diet-induced hypertension in rats is associated with increased renal vasoconstrictor response to angiotensin II after imitated endothelial dysfunction.. 2022 , 141, 104333	
42	Smoking modifies the effect of two independent SNPs rs5063 and rs198358 of NPPA on central obesity in the Chinese Han population. 2018 , 97, 987-994	0
41	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.. 2021 , 12, 785879	0
40	Inverse Regulation of Serum Osteoprotegerin and B-Type Natriuretic Peptide Concentrations by Free Fatty Acids Elevation in Young Healthy Humans.. 2022 , 14,	0
39	Role of biomarkers in the heart failure clinic. 2022 , 37, 4-17	2
38	The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metaanalysis.. 2022 ,	0
37	Invasive hemodynamic assessments during exercise: normal patterns and clinical value. 2022 , 545-563	
36	Beneficial Effects of the Ketogenic Diet in Metabolic Syndrome: A Systematic Review. 2022 , 3, 292-309	2
35	Cardiac Natriuretic Peptide System: A Link between Adipose Tissue, Obesity, and Insulin Resistance.	

34	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence.. 2022 , 1	2
33	New Conversion Formula Between B-Type Natriuretic Peptide and N-Terminal-Pro-B-Type Natriuretic Peptide [Analysis From a Multicenter Study] 2022 ,	0
32	Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Nepilysin Inhibitors in Patients With Heart Failure. 2022 , 9,	0
31	Exogenous ANP Treatment Ameliorates Myocardial Insulin Resistance and Protects against IschemiaReperfusion Injury in Diet-Induced Obesity. 2022 , 23, 8373	1
30	Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?. 2,	
29	Prospective observational study of amino-terminal brain natriuretic peptide levels in obese and non-obese women during pregnancy.	
28	Water intake, thirst, and copeptin responses to two dehydrating stimuli in lean men and men with obesity. 2022 , 30, 1806-1817	0
27	Discovery of an alternate mechanism for the inhibition of particulate guanylyl cyclases by the natriuretic peptide [clearance]receptor.	0
26	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). 2022 , 6-56	0
25	The landscape of N6-Methyladenosine Modification Patterns and Altered Transcript Profiles in Cardiac-specific deletion of natriuretic peptide receptor A.	0
24	Natriuretic PeptidesNew Targets for Neurocontrol of Blood Pressure via Baroreflex Afferent Pathway. 2022 , 23, 13619	0
23	Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation.	0
22	Review A State of Natriuretic Peptide Deficiency.	0
21	Cardiovascular Risks Associated With Obesity in Children and Adolescents. 2009 , 38, 48-56	2
20	Abdominal obesity increases metabolic risk factors in obese versus non-obese adults in Karbala. 2022 ,	0
19	Disinhibition augments thirst perception from two dehydrating stimuli in men. 2023 , 182, 106429	0
18	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). 2022 , 6-56	0
17	Phenomapping in heart failure with preserved ejection fraction [Insights, limitations, and future directions.	1

16	Impacts of metabolic disorders on short- and long-term mortality after coronary artery surgery in the elderly. 2022 , 22,	0
15	Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction. 13,	0
14	Role of Cardiac Natriuretic Peptides in Heart Structure and Function. 2022 , 23, 14415	2
13	The Evaluation of Cardiovascular System Before and After Renal Transplantation and Its Relationship Between Brain Natriuretic Peptide.	0
12	Endocrine functions of the heart: from bench to bedside.	2
11	The Role of Dietary Salt in Metabolism and Energy Balance, Insights Beyond Cardiovascular Disease.	0
10	Non-invasive determinants of pulmonary hypertension in interstitial lung disease.	0
9	Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. 2023 , 38, 157-166	0
8	Association of Long-term Change in N-Terminal ProB-Type Natriuretic Peptide With Incident Heart Failure and Death. 2023 , 8, 222	1
7	Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control- National Health and Nutrition Examination Survey, 1999-2004.	0
6	Association between Intra- and Extra-Cellular Water Ratio Imbalance and Natriuretic Peptides in Patients Undergoing Hemodialysis. 2023 , 15, 1274	0
5	Associations of atrial natriuretic peptide with measures of insulin and adipose depots. 2023 , 11,	0
4	Exploring the underlying mechanisms linking adiposity and cardiovascular disease: A prospective cohort study of 404,332 UK Biobank participants.. 2023 , 101715	0
3	POLYMORPHISM OF GENES RESPONSIBLE FOR NEUROHUMORAL MECHANISMS OF DEVELOPMENT OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PERSONS WITH TYPE 2 DIABETES MELLITUS. 2023 , 73-82	0
2	Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide.	0
1	Features of heart diastolic dysfunction in Arkhangelsk residents with metabolic syndrome. 2023 , 26, 86	0